CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 3, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	648	81	104	106	283	303
Market Cap Growth	602.94%	-22.37%	-1.80%	-62.58%	-6.69%	-19.81%
Enterprise Value	497	-26	-75	-70	69	7
Last Close Price	3.93	1.03	1.55	1.60	4.33	6.55
PE Ratio	8.04	2.53	-	-	-	-
Forward PE	-	-	16.30	-	-	-
PS Ratio	2.70	0.58	1.03	1.99	7.57	4.43
PB Ratio	5.40	-176.77	-2.19	-1.23	-615.53	-38.95
P/TBV Ratio	5.47	-	-	-	-	-
P/FCF Ratio	-	-	-	-	-	102.63
P/OCF Ratio	-	-	-	-	-	57.57
EV/Sales Ratio	3.52	-	-	-	1.84	0.11
EV/FCF Ratio	-	-	-	-	-	2.48
Debt / Equity Ratio	0.06	-20.58	-0.29	-0.21	-47.22	-3.20
Debt / EBITDA Ratio	0.14	0.31	-	-	-	-
Debt / FCF Ratio	-	-	-	-	-	8.43
Asset Turnover	0.84	0.86	0.44	0.18	0.11	0.20
Quick Ratio	4.08	1.21	1.14	1.51	3.93	4.65
Current Ratio	4.20	1.25	1.17	1.55	3.99	4.76
Return on Equity (ROE)	108.21%	-	-	-	-	-299.13%
Return on Assets (ROA)	16.13%	9.69%	-1.75%	-19.54%	-20.78%	-14.38%
Return on Capital (ROIC)	50.23%	-	-	-	-378.62%	-104.99%
Return on Capital Employed (ROCE)	31.70%	71.90%	-	-	-	-
Earnings Yield	7.40%	39.54%	-0.55%	-93.93%	-41.01%	-21.41%
FCF Yield	-11.99%	-107.36%	-54.78%	-106.42%	-42.70%	0.97%
Buyback Yield / Dilution	-17.52%	-14.82%	-12.27%	-2.48%	-39.01%	-1.79%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q